Early Study of Exosome Multiomics and Clinical Outcomes in Adults With Sudden Cardiac Death Related to Acute Coronary Syndrome

What this Trial Is About

Acute coronary syndrome ACS is a leading cause of death worldwide, involving conditions like acute myocardial infarction and unstable angina that can trigger sudden cardiac death SCD. This research focuses on understanding the early clinical signs and prognosis of patients who experience sudden death linked to ACS. The study aims to evaluate exosome multiomics, including metabolites, microRNAs, and proteins, to better predict and manage SCD risk in ACS patients. Participants will receive standardized medical care for cardiac arrest, which includes early cardiopulmonary resuscitation CPR, defibrillation, advanced cardiac life support ACLS, and post-resuscitation care with continuous monitoring. The study is observational and monitors patients over a period of two years to assess the presence of exosome-associated biomarkers. No experimental drugs are administered instead, patient outcomes following standard emergency care are observed. Participants will be monitored through clinical evaluations and laboratory tests assessing exosome-related molecules over two years. Researchers will examine these biomarkers to understand their connection with sudden death outcomes. The study also tracks vital signs and clinical symptoms before and after treatment, aiming to improve early prediction of SCD in ACS patients. The total duration of participation spans up to two years with regular follow-ups to assess prognosis and biomarker changes.

Early Evaluation of Exosome Multiomics and Clinical Prognosis in Patients With Sudden Death